Literature DB >> 23559324

Liver transplantation prevents progressive neurological impairment in argininemia.

E Santos Silva1, M L Cardoso, L Vilarinho, M Medina, C Barbot, E Martins.   

Abstract

Argininemia is a rare hereditary disease due to a deficiency of hepatic arginase, which is the last enzyme of the urea cycle and hydrolyzes arginine to ornithine and urea. The onset of the disease is usually in childhood, and clinical manifestations include progressive spastic paraparesis and mental retardation. Liver involvement is less frequent and usually not as severe as observed in other UCDs. For this reason, and because usually there is a major neurological disease at diagnosis, patients with argininemia are rarely considered as candidates for OLT despite its capacity to replace the deficient enzyme by an active one. We report on long-term follow-up of two patients with argininemia. Patient 1 was diagnosed by the age of 20 months and despite appropriate conventional treatment progressed to spastic paraparesis with marked limp. OLT was performed at 10 years of age with normalization of plasmatic arginine levels and guanidino compounds. Ten years post-OLT, under free diet, there is no progression of neurological lesions. The second patient (previously reported by our group) was diagnosed at 2 months of age, during a neonatal cholestasis workup study. OLT was performed at the age of 7 years, due to liver cirrhosis with portal hypertension, in the absence of neurological lesions and an almost-normal brain MRI. After OLT, under free diet, there was normalization of plasmatic arginine levels and guanidino compounds. Twelve years post-OLT, she presents a normal neurological examination. We conclude that OLT prevents progressive neurological impairment in argininemia and should be considered when appropriate conventional treatment fails.

Entities:  

Year:  2013        PMID: 23559324      PMCID: PMC3755545          DOI: 10.1007/8904_2013_218

Source DB:  PubMed          Journal:  JIMD Rep        ISSN: 2192-8304


  10 in total

1.  Liver transplantation in a case of argininaemia.

Authors:  E Santos Silva; E Martins; M L Cardoso; C Barbot; L Vilarinho; M Medina
Journal:  J Inherit Metab Dis       Date:  2001-12       Impact factor: 4.982

Review 2.  A role for guanidino compounds in the brain.

Authors:  Midori Hiramatsu
Journal:  Mol Cell Biochem       Date:  2003-02       Impact factor: 3.396

3.  Hyperargininemia presenting as persistent neonatal jaundice and hepatic cirrhosis.

Authors:  A C Braga; L Vilarinho; E Ferreira; H Rocha
Journal:  J Pediatr Gastroenterol Nutr       Date:  1997-02       Impact factor: 2.839

4.  Identification of a novel R21X mutation in the liver-type arginase gene (ARG1) in four Portuguese patients with argininemia.

Authors:  M L Cardoso; E Martins; R Vasconcelos; L Vilarinho; J Rocha
Journal:  Hum Mutat       Date:  1999-10       Impact factor: 4.878

5.  Neonatal cholestasis: an uncommon presentation of hyperargininemia.

Authors:  Esmeralda Gomes Martins; Ermelinda Santos Silva; Silvia Vilarinho; Jean Marie Saudubray; Laura Vilarinho
Journal:  J Inherit Metab Dis       Date:  2011-01-13       Impact factor: 4.982

6.  Guanidino compound analysis as a complementary diagnostic parameter for hyperargininemia: follow-up of guanidino compound levels during therapy.

Authors:  B Marescau; P P De Deyn; A Lowenthal; I A Qureshi; I Antonozzi; C Bachmann; S D Cederbaum; R Cerone; N Chamoles; J P Colombo
Journal:  Pediatr Res       Date:  1990-03       Impact factor: 3.756

Review 7.  Clinical, biochemical, and molecular spectrum of hyperargininemia due to arginase I deficiency.

Authors:  Fernando Scaglia; Brendan Lee
Journal:  Am J Med Genet C Semin Med Genet       Date:  2006-05-15       Impact factor: 3.908

Review 8.  Guanidino compounds as uremic (neuro)toxins.

Authors:  Peter Paul De Deyn; Raymond Vanholder; Sunny Eloot; Griet Glorieux
Journal:  Semin Dial       Date:  2009 Jul-Aug       Impact factor: 3.455

9.  Guanidino compounds in hyperargininemia.

Authors:  N Mizutani; C Hayakawa; Y Ohya; K Watanabe; Y Watanabe; A Mori
Journal:  Tohoku J Exp Med       Date:  1987-11       Impact factor: 1.848

10.  A structural MRI study of human brain development from birth to 2 years.

Authors:  Rebecca C Knickmeyer; Sylvain Gouttard; Chaeryon Kang; Dianne Evans; Kathy Wilber; J Keith Smith; Robert M Hamer; Weili Lin; Guido Gerig; John H Gilmore
Journal:  J Neurosci       Date:  2008-11-19       Impact factor: 6.167

  10 in total
  12 in total

Review 1.  Liver transplantation for pediatric inherited metabolic disorders: Considerations for indications, complications, and perioperative management.

Authors:  Kimihiko Oishi; Ronen Arnon; Melissa P Wasserstein; George A Diaz
Journal:  Pediatr Transplant       Date:  2016-06-21

Review 2.  Urea cycle disorders: a case report of a successful treatment with liver transplant and a literature review.

Authors:  Francesco Giuseppe Foschi; Maria Cristina Morelli; Sara Savini; Anna Chiara Dall'Aglio; Arianna Lanzi; Matteo Cescon; Giorgio Ercolani; Alessandro Cucchetti; Antonio Daniele Pinna; Giuseppe Francesco Stefanini
Journal:  World J Gastroenterol       Date:  2015-04-07       Impact factor: 5.742

3.  Metabolic liver diseases presenting with neonatal cholestasis: at the crossroad between old and new paradigms.

Authors:  Helena Moreira-Silva; Inês Maio; Anabela Bandeira; Esmeralda Gomes-Martins; Ermelinda Santos-Silva
Journal:  Eur J Pediatr       Date:  2019-01-28       Impact factor: 3.183

4.  The effect of liver transplantation for argininemia-the largest experiences in a single center.

Authors:  Bin Cui; Lin Wei; Li-Ying Sun; Wei Qu; Zhi-Gui Zeng; Ying Liu; Zhi-Jun Zhu
Journal:  Transl Pediatr       Date:  2022-04

5.  Lipid nanoparticle-targeted mRNA therapy as a treatment for the inherited metabolic liver disorder arginase deficiency.

Authors:  Brian Truong; Gabriella Allegri; Xiao-Bo Liu; Kristine E Burke; Xuling Zhu; Stephen D Cederbaum; Johannes Häberle; Paolo G V Martini; Gerald S Lipshutz
Journal:  Proc Natl Acad Sci U S A       Date:  2019-09-09       Impact factor: 11.205

6.  Human recombinant arginase enzyme reduces plasma arginine in mouse models of arginase deficiency.

Authors:  Lindsay C Burrage; Qin Sun; Sarah H Elsea; Ming-Ming Jiang; Sandesh C S Nagamani; Arthur E Frankel; Everett Stone; Susan E Alters; Dale E Johnson; Scott W Rowlinson; George Georgiou; Brendan H Lee
Journal:  Hum Mol Genet       Date:  2015-09-10       Impact factor: 6.150

Review 7.  Review of Multi-Modal Imaging in Urea Cycle Disorders: The Old, the New, the Borrowed, and the Blue.

Authors:  Kuntal Sen; Afrouz A Anderson; Matthew T Whitehead; Andrea L Gropman
Journal:  Front Neurol       Date:  2021-04-28       Impact factor: 4.086

8.  Hyperargininemia Presenting as Intermittent Ataxia and Cerebellar Atrophy.

Authors:  Leema P Cornelius; Vivekasaravanan Raju; Asir Julin
Journal:  Ann Indian Acad Neurol       Date:  2020-06-10       Impact factor: 1.383

9.  Proof-of-Concept Gene Editing for the Murine Model of Inducible Arginase-1 Deficiency.

Authors:  Yuan Yan Sin; Phillipe R Price; Laurel L Ballantyne; Colin D Funk
Journal:  Sci Rep       Date:  2017-05-31       Impact factor: 4.379

10.  Untargeted metabolomic profiling reveals multiple pathway perturbations and new clinical biomarkers in urea cycle disorders.

Authors:  Lindsay C Burrage; Lillian Thistlethwaite; Bridget M Stroup; Qin Sun; Marcus J Miller; Sandesh C S Nagamani; William Craigen; Fernando Scaglia; V Reid Sutton; Brett Graham; Adam D Kennedy; Aleksandar Milosavljevic; Brendan H Lee; Sarah H Elsea
Journal:  Genet Med       Date:  2019-01-23       Impact factor: 8.822

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.